Pfizer, BioNTech's COVID-19 vaccine shows 95% efficacy

By The Science Advisory Board staff writers

December 11, 2020 -- In a trial of more than 40,000 participants, Pfizer-BioNTech's COVID-19 vaccine showed a 95% efficacy against the SARS-CoV-2 virus, according to results published in the New England Journal of Medicine on December 10.

The phase III trial included data from 43,448 participants who were 16 years of age and older. Half of the participants received 30-µg BNT162b2 and half received the placebo in a two-dose regimen 21 days apart. The vaccine candidate was well-tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection seven days or more after the second dose.

The results were generally consistent across subgroups defined by age, gender, race, ethnicity, baseline body mass index (BMI), or presence of other underlying comorbidities. In addition, partial protection began as early as 12 days after the first dose, the researchers found.

Among 36,523 participants who had no evidence of existing or prior SARS-CoV-2 infection, there were 170 cases of COVID-19 observed with onset at least seven days after the second dose. The researchers found eight cases occurred in vaccine recipients, and 162 in placebo recipients.

Among participants with and without evidence of prior SARS CoV-2 infection, nine cases of COVID-19 were found among vaccine recipients and 169 among placebo recipients.

Pfizer and BioNTech are planning additional studies to evaluate the vaccine in pregnant women, children younger than 12, and those in special risk groups, such as the immunocompromised.


Copyright © 2020 scienceboard.net
 
To access all The ScienceBoard content create a free account now:


Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.


Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Already have an account? Sign in here